BRIEF-Stoke Therapeutics Plans To Initiate Phase 3 Study Of Zorevunersen To Treat Dravet Syndrome On Alignment With Global Regulatory Agencies

Reuters

07 Jan

Jan 7 (Reuters) - Stoke Therapeutics Inc :

* STOKE THERAPEUTICS ANNOUNCES ALIGNMENT WITH GLOBAL REGULATORY AGENCIES AND PLANS TO INITIATE A PHASE 3 STUDY OF ZOREVUNERSEN AS POTENTIALLY THE FIRST DISEASE-MODIFYING MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME

* STOKE THERAPEUTICS : FDA BREAKTHROUGH THERAPY DESIGNATION POSITIONS ZOREVUNERSEN ON EFFICIENT DEVELOPMENT PATH; PLANS TO START PHASE 3 IN MID-2025

Source text: Further company coverage:

((Reuters.Brief@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2501820894"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2501820894\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2501820894?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-07 20:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2501820894","market":"us","top_or_hot":-1,"title":"BRIEF-Stoke Therapeutics Plans To Initiate Phase 3 Study Of Zorevunersen To Treat Dravet Syndrome On Alignment With Global Regulatory Agencies","media":"Reuters","content":"<html><body><p>Jan 7 (Reuters) - Stoke <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * STOKE THERAPEUTICS ANNOUNCES ALIGNMENT WITH GLOBAL REGULATORY AGENCIES AND PLANS TO INITIATE A PHASE 3 STUDY OF ZOREVUNERSEN AS POTENTIALLY THE FIRST DISEASE-MODIFYING MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME</p><p>   * STOKE THERAPEUTICS : FDA BREAKTHROUGH THERAPY DESIGNATION POSITIONS ZOREVUNERSEN ON EFFICIENT DEVELOPMENT PATH; PLANS TO START PHASE 3 IN MID-2025</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Brief@thomsonreuters.com))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Stoke Therapeutics Plans To Initiate Phase 3 Study Of Zorevunersen To Treat Dravet Syndrome On Alignment With Global Regulatory Agencies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Stoke Therapeutics Plans To Initiate Phase 3 Study Of Zorevunersen To Treat Dravet Syndrome On Alignment With Global Regulatory Agencies\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-01-07 20:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Jan 7 (Reuters) - Stoke <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc   :</p><p>   * STOKE THERAPEUTICS ANNOUNCES ALIGNMENT WITH GLOBAL REGULATORY AGENCIES AND PLANS TO INITIATE A PHASE 3 STUDY OF ZOREVUNERSEN AS POTENTIALLY THE FIRST DISEASE-MODIFYING MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME</p><p>   * STOKE THERAPEUTICS : FDA BREAKTHROUGH THERAPY DESIGNATION POSITIONS ZOREVUNERSEN ON EFFICIENT DEVELOPMENT PATH; PLANS TO START PHASE 3 IN MID-2025</p><p>Source text:    Further company coverage:   </p><p> ((Reuters.Brief@thomsonreuters.com))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2501820894","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2501820894","pubTimestamp":1736252483,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"Jan 7  - Stoke Therapeutics Inc   :   * STOKE THERAPEUTICS ANNOUNCES ALIGNMENT WITH GLOBAL REGULATORY AGENCIES AND PLANS TO INITIATE A PHASE 3 STUDY OF ZOREVUNERSEN AS POTENTIALLY THE FIRST DISEASE-MODIFYING MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME   * STOKE THERAPEUTICS : FDA BREAKTHROUGH THERAPY DESIGNATION POSITIONS ZOREVUNERSEN ON EFFICIENT DEVELOPMENT PATH; PLANS TO START PHASE 3 IN MID-2025Source text:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","STOK":"Stoke Therapeutics, Inc.","LENZ":"Therapeutics"},"translate_title":"BRIEF-Stoke Therapeutics计划与全球监管机构保持一致，启动Zorevunersen治疗Dravet综合征的3期研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"STOK":0.9},"content_text":"Jan 7 (Reuters) - Stoke Therapeutics Inc   :   * STOKE THERAPEUTICS ANNOUNCES ALIGNMENT WITH GLOBAL REGULATORY AGENCIES AND PLANS TO INITIATE A PHASE 3 STUDY OF ZOREVUNERSEN AS POTENTIALLY THE FIRST DISEASE-MODIFYING MEDICINE FOR THE TREATMENT OF DRAVET SYNDROME   * STOKE THERAPEUTICS : FDA BREAKTHROUGH THERAPY DESIGNATION POSITIONS ZOREVUNERSEN ON EFFICIENT DEVELOPMENT PATH; PLANS TO START PHASE 3 IN MID-2025Source text:    Further company coverage:    ((Reuters.Brief@thomsonreuters.com))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}